NVS - Novartis AG

NYSE - NYSE Delayed Price. Currency in USD
77.06
-0.09 (-0.12%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close77.15
Open77.38
Bid0.00 x 3100
Ask0.00 x 1300
Day's Range76.91 - 77.43
52 Week Range75.73 - 94.19
Volume1,478,946
Avg. Volume1,704,340
Market Cap179.633B
Beta0.89
PE Ratio (TTM)23.71
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.98 (3.80%)
Ex-Dividend Date2018-03-06
1y Target EstN/A
Trade prices are not sourced from all markets
  • TheStreet.com2 days ago

    CBS-Viacom Battle Comes to a Head; FDA Approves Novartis Migraine Drug --ICMYI

    After a heated week of litigation battles, CBS on Thursday proceeded with a board meeting it had scheduled to vote on whether to dilute the voting power of National Amusements Inc., a company controlled by Shari Redstone. This came after a court decision that said CBS could not prevent Redstone from changing CBS's bylaws to prevent that from occurring. All of which means CBS directors and Redstone will be back in court soon to fight over voting control, with Redstone pushing to combine CBS with Viacom, unless of course, both sides instead consider the option to auction the media company.

  • CNBC2 days ago

    Cohen lawyers object to Stormy Daniels' attorney Michael Avenatti intervening in New York case

    Michael Cohen's lawyers in a court filing say why they oppose the admission of Stormy Daniels' attorney, Michael Avenatti, to a New York federal court for the purpose of arguing her position. Cohen reportedly had files in his possession related to Daniels, whom he paid $130,000 for her silence about an alleged affair with President Trump, Cohen's longtime client. Avenatti recently released a report showing that Novartis, AT&T, Korea Aerospace Industries and Columbus Nova made payments to Cohen after Trump became president.

  • Reuters2 days ago

    After hullabaloo, Greek lawmakers drop Novartis probe against ex ministers

    Greece's parliament has no jurisdiction to investigate the role of ten politicians in alleged bribes by Swiss drugmaker Novartis, lawmakers ruled on Saturday, in a controversy which has further polarized a deeply divided political landscape. Greek prosecutors were probing allegations from three individuals suggesting doctors and public officials had accepted kickbacks in a period spanning 2006 to 2015. Ten public officials who served under socialist and conservative governments over that period say the allegations, which they denied, was a 'sick' mud-slinging campaign fabricated by the leftist-led government.

  • CNBC2 days ago

    Migraine prevention drug could be worth $1 to $2 billion over next five years: Wall Street analyst

    One Wall Street analyst predicts the anti-migraine category could be a $1 billion to $2 billion business over the next five years. Michael Yee, managing director at Jefferies, expects others companies to get into the migraine treatment sector. The anti-migraine drug Aimovig from Amgen AMGN and Novartis NVS could become a $1 billion to $2 billion business over the next five years, said a Wall Street analyst.

  • FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs
    InvestorPlace3 days ago

    FDA Shame List: 40 Drug Makers That Try to Block Generic Drugs

    The Food and Drug Administration (FDA) announced a shame list of companies that try to block generic drugs in order to ramp up profits.

  • Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug
    Zacks3 days ago

    Pharma Stock Roundup: Zoetis to Buy Abaxis, NVS Gets FDA Nod for Migraine Drug

    Novartis' (NVS) CGRP antibody, Aimovig gains FDA approval for prevention of migraine. Zoetis (ZTS) and Lilly (LLY) announce deals to buy smaller companies.

  • Moody's3 days ago

    Novartis AG -- Moody's: Aimovig approval credit positive for Amgen and Novartis

    Moody's Investors Service commented that the recent US Food and Drug Administration (FDA) approval of Aimovig for chronic migraines is credit positive for the Amgen Inc. (Baa1 stable) and Novartis AG (Aa3 negative). For additional information, please see Moody's Issuer Comment available on www.moodys.com. This publication does not announce a credit rating action.

  • The Wall Street Journal3 days ago

    New Migraine Drugs Offer Hope to Sufferers

    The FDA has approved a new drug called Aimovig that is touted as the first treatment designed specifically to prevent migraines.

  • TheStreet.com3 days ago

    Amgen, Novartis Clinch FDA Nod on Migraine Prevention Drug

    said late Thursday, May 17, they have obtained approval from the U.S. Food and Drug Administration for Aimovig, a migraine prevention drug for adults. The drug is the first treatment green-lighted by the agency to prevent migraines by blocking the calcitonin gene-related peptide receptor, thought to play a key role in the disease. "We believe Amgen will benefit significantly from its first mover advantage and ultimately retain 35-40% market share long term," Leerink Partners LLC analyst Geoffrey C. Porges wrote in a note on Friday.

  • MarketWatch3 days ago

    ‘Holy of holies’ — Inside the financial crime database that sprung a leak

    A blockbuster story about the whistleblower who revealed President Donald Trump’s personal lawyer received payments from various companies has placed attention on a fairly obscure unit with the Treasury Department that’s at the heart of regulating the financial system. The New Yorker’s Ronan Farrow interviewed someone he called a “law-enforcement official” who leaked, per the report, after not being able to find two suspicious-activity reports on Michael Cohen, who received big payments from AT&T, Novartis and Korea Aerospace Industries.

  • Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up
    Zacks3 days ago

    Amgen's Migraine Drug Aimovig Gets FDA Approval, Shares Up

    Amgen's (AMGN) preventive treatment for migraine, Aimovig, gets approval in the United States.

  • Label Expansion May Boost Cabometyx’s Revenue in 2018
    Market Realist3 days ago

    Label Expansion May Boost Cabometyx’s Revenue in 2018

    On January 16, Exelixis (EXEL) and Ipsen announced positive results from the CELESTIAL Phase 3 trial highlighting the statistically significant and clinically meaningful improvement in the trial’s primary end point of overall survival due to cabozantinib therapy compared to a placebo in second-line and third-line hepatocellular carcinoma (or HCC) patients.

  • Amgen Stock Rises over 2% on Drug Approvals
    Market Realist3 days ago

    Amgen Stock Rises over 2% on Drug Approvals

    On May 17, Amgen (AMGN) stock rose ~0.5% to the closing price of $174.65 per share following FDA approval of Aimovig. The company’s stock price has risen ~2.3% in the last week following recent drug approvals. Amgen’s stock price has risen ~11.2% over the last 12 months.

  • Benzinga3 days ago

    Benzinga's Daily Biotech Pulse: AstraZeneca's Q1, Novartis-Amgen Migraine Drug Approved

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on May 17) Abaxis Inc (NASDAQ: ABAX ) (rallying for second straight session ...

  • Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018
    Market Realist3 days ago

    Cabometyx Is Expected to Witness a Robust Revenue Rise in 2018

    In the first quarter, Exelixis’s (EXEL) Cabometyx witnessed more than a 20% sequential rise in prescription volume driven by both new patient starts and a robust rise in the total number of patients on the therapy. According to a report, ~295,000 people across the world are diagnosed with kidney cancer every year, while 134,000 kidney cancer patients die every year. According to the American Cancer Society’s Cancer Facts & Figures 2018, the annual incidence of kidney cancer in the United States is ~65,000, while the annual death toll of the disease is 15,000. Another report estimates that almost 70%–75% of renal cell cancer (or RCC) patients suffer from clear cell RCC.

  • Investopedia3 days ago

    Novartis, Amgen Get FDA Nod for Migraine Drug

    Novartis AG (ADR) ( NVS) today announced that it has received the necessary approval from the U.S. Food and Drug Administration (FDA) for its key drug Aimovig (erenumab) as a preventive treatment of migraine in adults. The drug works by blocking a compound called calcitonin gene-related peptide receptor (CGRP-R), which is believed to play a critical role in migraine. The drug is available for self-administering once a month using Amgen Inc.’s ( AMGN) SureClick auto-injector. During the phase 2 and phase 3 clinical trials in patients with chronic and episodic migraine, the use of Aimovig resulted in significant decline in monthly migraine days.

  • The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers’ Stocks Are Rising
    Fortune3 days ago

    The FDA Approved a Promising New Shot to Treat Migraines and Now the Drugmakers’ Stocks Are Rising

    Aimovig apparently cuts migraine days significantly.

  • MarketWatch3 days ago

    FDA approves anti-migraine drug from Novartis, Amgen

    Shares of drugmakers Amgen Inc. and Novartis AG rose in after-hours trading Thursday after jointly announcing FDA approval of Aimovig, a first-of-its-kind treatment for migraines. In a statement, Novartis said the Federal Drug Administration approved Aimovig's use for the preventive treatment of migraines in adults. "Aimovig is the first therapy of its kind targeting the CGRP receptor, and has demonstrated robust efficacy across the spectrum of migraine," Novartis Chief Executive Paul Hudson said in the statement.

  • US approves 1st drug developed to prevent chronic migraines
    Associated Press3 days ago

    US approves 1st drug developed to prevent chronic migraines

    TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines.

  • FDA names drugmakers accused of blocking cheaper generics
    Associated Press3 days ago

    FDA names drugmakers accused of blocking cheaper generics

    TRENTON, N.J. (AP) — U.S. drug regulators are publicizing information on brand-name drugmakers that use what government officials call "gaming tactics" to block cheaper copycat versions.

  • Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space
    Market Realist4 days ago

    Exelixis Focused on Positioning Cabometyx in Kidney Cancer Space

    Exelixis (EXEL) aims to position Cabometyx as the preferred tyrosine-kinase inhibitor (or TKI) in the renal cell carcinoma (or RCC) segment. At the end of 2017, Cabometyx had managed to acquire a 42% share of the second-line and new patient advanced RCC market, higher than its 39% market share at the end of the third quarter of 2017. Cabometyx demonstrated superiority over Pfizer’s (PFE) Sutent as a first-line RCC therapy in its Phase 2 CABOSUN trial in terms of progression-free survival, which has helped boost physicians’ confidence in Cabometyx.

  • The Wall Street Journal4 days ago

    [$$] Novartis Top Lawyer Departs Over Cohen Payments

    ZURICH——A top executive at Swiss drugmaker Novartis AG is stepping down amid the controversy over payments that corporations made to a company owned by U.S. President Donald Trump’s longtime personal lawyer . Novartis said Wednesday that general counsel Felix Ehrat, 61 years old, is retiring from the company in connection with $1.2 million in payments it made over the course of a year to Michael Cohen’s shell company, Essential Consultants LLC. It was the second high-profile departure in less than a week in relation to payments to the company.

  • Novartis Gains Ground, Completes the AveXis Acquisition
    Market Realist4 days ago

    Novartis Gains Ground, Completes the AveXis Acquisition

    Novartis (NVS) is one of the leading pharmaceutical companies worldwide. AveXis (AVXS) is a US-based clinical-stage gene therapy company. On May 15, Novartis announced that it completed the acquisition of AveXis.

  • Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report
    CNBC4 days ago

    Missing documents prompted leak of Trump lawyer Michael Cohen's bank records: Report

    A law enforcement official leaked a suspicious activity report about Trump lawyer Michael Cohen and payments by Novartis and AT&T to his Essential Consultants company, The New Yorker reports.

  • The Wall Street Journal4 days ago

    [$$] The Novartis-Cohen Connection Explained

    Although other companies, including AT&T, also paid Mr. Cohen for his services, Novartis is distinguished for likely having paid more than any of the others, and it has drawn the attention of prosecutors at home. Novartis is a Basel-based multinational pharmaceutical company that makes a number of drugs, including treatments for cancer, heart conditions, and autoimmune diseases.